Our top pick for
Ensysce Biosciences Inc is a shell companies business based in the US. Ensysce Biosciences shares (LACQ) are listed on the PINK and all prices are listed in US Dollars.
|Latest market close||$13.85|
|52-week range||$10.47 - $21.80|
|50-day moving average||$13.97|
|200-day moving average||$13.65|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
|1 week (2021-10-12)||N/A|
|1 month (2021-09-19)||N/A|
|3 months (2021-07-19)||N/A|
|6 months (2021-04-23)||8.88%|
|1 year (2020-10-23)||28.84%|
|2 years (2019-10-23)||35.12%|
|3 years (2018-10-23)||42.34%|
|5 years (2016-10-19)||N/A|
Valuing Ensysce Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ensysce Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ensysce Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 119x. In other words, Ensysce Biosciences shares trade at around 119x recent earnings.
|Gross profit TTM||$0|
|Return on assets TTM||-1.25%|
|Return on equity TTM||23.4%|
|Market capitalisation||$90.2 million|
TTM: trailing 12 months
There are currently 2,958 Ensysce Biosciences shares held short by investors – that's known as Ensysce Biosciences's "short interest". This figure is 21% up from 2,445 last month.
There are a few different ways that this level of interest in shorting Ensysce Biosciences shares can be evaluated.
Ensysce Biosciences's "short interest ratio" (SIR) is the quantity of Ensysce Biosciences shares currently shorted divided by the average quantity of Ensysce Biosciences shares traded daily (recently around 2310.9375). Ensysce Biosciences's SIR currently stands at 1.28. In other words for every 100,000 Ensysce Biosciences shares traded daily on the market, roughly 1280 shares are currently held short.
However Ensysce Biosciences's short interest can also be evaluated against the total number of Ensysce Biosciences shares, or, against the total number of tradable Ensysce Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ensysce Biosciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Ensysce Biosciences shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Ensysce Biosciences shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ensysce Biosciences.
Find out more about how you can short Ensysce Biosciences stock.
We're not expecting Ensysce Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Ensysce Biosciences's shares have ranged in value from as little as $10.47 up to $21.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Ensysce Biosciences's is -0.1134. This would suggest that Ensysce Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ensysce Biosciences has bucked the trend.
Ensysce Biosciences, Inc. operates as a biotechnology company that develops abuse-resistant drug technologies. It offers TAAP, a trypsin-activated abuse protection technology that prevents abuse through a two-step internal trypsin-activation process to meet the medical needs of patients living with chronic pain; and MPAR, a multi-pill abuse resistant technology that provides a layer of protection for overdose. The company was incorporated in 2003 and is based in La Jolla, California. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.